Mifepristone

Annals of Pharmacotherapy

Volumn 35, Issue 6, 2001, Pages 707-719

  DeHart, Renee M ^a,b   Morehead, M Shawn ^a,b  

^a SAMFORD UNIVERSITY   (United States)

^b NONE   (United States)

Author keywords

Abortion; Mifepristone; Misoprostol; Pregnancy termination

Indexed keywords

MIFEPRISTONE; MISOPROSTOL;

ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG USE; FOOD AND DRUG ADMINISTRATION; HUMAN; INDUCED ABORTION; PREGNANCY TERMINATION; PRIORITY JOURNAL; TREATMENT INDICATION;

ABORTIFACIENT AGENTS, STEROIDAL; ABORTION, INDUCED; CLINICAL TRIALS; COST-BENEFIT ANALYSIS; COUNSELING; DRUG INTERACTIONS; FEMALE; HUMANS; MIFEPRISTONE; TREATMENT OUTCOME;

EID: 0034995587     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.10397     Document Type: Article

References (62)

1. Highlights of trends in pregnancies and pregnancy rates by outcome: Estimates for the United States, 1976-96
2. Conditions for choosing between drug-induced and surgical abortions
3. Therapeutic abortions with a folic acid antagonist, 4-aminopterolylglutamic acid (4-Amino P.G.A.) administered by the oral route
4. Medical abortion alternatives for mifepristone
5. Mode of action of medical methods of abortion
6. Fetal growth and development
7. Mifepristone: A review of its pharmacodynamic and pharmacokinetics properties, and therapeutic potential
8. Mifepristone: Clinical pharmacology
9. Cervical ripening with mifepristone (RU 486) after pretreatment with naproxen. A double-blind randomized study
10. The effects of mifepristone administration of leukocyte populations, matrix metalloproteinases and inflammatory mediators in the first trimester cervix
11. The new steroid analog RU 486 inhibits glucocorticoid action in man
12. Clinical pharmacokinetics of mifepristone
13. Intravaginal administration of RU486 in humans and rats: Inadequate absorption in humans
14. In vitro study of the binding of RU 486 and RU 42633 to human serum proteins
15. Antiprogesterone steroid RU486. Pharmacokinetics and receptor binding in humans
16. Pharmacokinetics and metabolism of RU 486
17. Pharmacokinetics of the antiprogesterone RU 486 in women during multiple dose administration
18. Pharmacokinetic study of orally administered RU 486 in non-pregnant women
19. Termination of early pregnancy (up to 63 days of amenorrhea) and increasing doses of misoprostol
20. Early pregnancy termination with mifepristone and misoprostol in the United States
21. Comparison of two doses of mifepristone in combination with misoprostol for early medical abortion: A randomized trial
22. Medical versus surgical abortion
23. Management of side effects and complications in medical abortion
24. Complications of first trimester abortion: A report of 170,000 cases
25. Induced abortion as an independent risk factor for breast cancer: A comprehensive review and meta-analysis
26. Abortion and subsequent substance abuse
27. Suicides after pregnancy in Finland, 1987-94: Register linkage study
28. Suicides after pregnancy
29. Antiprogestin-mediated inactivation of cytochrome P450 3A4
30. A randomized double-blind placebo-controlled study to assess the effect of oral contraceptive pills on the outcome of medical abortion with mifepristone and misoprostol
31. A pilot study of the effect of methotrexate or combined oral contraceptive on bleeding patterns after induction of abortion with mifepristone and a prostaglandin pessary
32. Acetaminophen as a pain enhancer during voluntary interruption of pregnancy with mifepristone and sulprostone
33. Package insert
34. Treatment of interstitial ectopic pregnancy with methotrexate: Report of a successful case
35. Methotrexate and misoprostol for early abortion
36. Methotrexate and misoprostol to terminate early pregnancy
37. A comparison of tamoxifen and misoprostol to misoprostol alone for early pregnancy termination
38. Legal issues in the provision of medical abortion
39. Package insert
40. Induction of labor with mifepristone - A randomized, double-blind study versus placebo
41. Cervical ripening with mifepristone before labor induction: A randomized study
42. Labor induction in women at term with mifepristone (RU 486): A double-blind, randomized, placebo-controlled study
43. Regression of uterine leiomyomata to the antiprogesterone RU486: Dose-response effect
44. Preliminary report on the treatment of endometriosis with low-dose mifepristone (RU 486)
45. Treatment of endometriosis with the antiprogesterone mifepristone (RU 486)
46. Clinical efficacy of the antiprogesterone RU 486 in the treatment of endometriosis and uterine fibroids
47. Phase II study of mifepristone (RU 486) in refractory ovarian cancer
48. Possible use of glucocorticoid receptor antagonists in the treatment of major depression: Preliminary results using RU 486
49. Mifepristone (RU 486) compared with high-dose estrogen and progestogen for emergency postcoital contraception
50. Comparison of Yuzpe regimen, danazol, and mifepristone (RU 486) in oral postcoital contraception
51. Contragestion with late luteal administration of RU 486 (mifepristone)
52. Contraceptive efficacy of low doses of mifepristone
53. Persistence of premenstrual syndrome during low-dose administration of the progesterone antagonist RU 486
54. Lack of effect of induced menses on symptoms in women with premenstrual syndrome
55. Phase II study of the progesterone antagonist mifepristone in patients with untreated metastatic breast carcinoma: A National Cancer Institute of Canada Clinical Trials Group study
56. Counseling for medical abortion
57. Postabortion syndrome: An emerging public health concern
58. Acceptability and feasibility of early pregnancy termination by mifepristone-misoprostol